Clinical outcome of hepatitis C as a function of mode of transmission

Hepatology

Volumn 28, Issue 2, 1998, Pages 562-567

  Gordon, Stuart C ^a,b   Bayati, Nasser ^a   Silverman, Ann L ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORBIDITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031927737     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280238     Document Type: Article

References (24)

1. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
2. Jove J, Sanchez-Taplas M, Bruguera M, Mas A, Costa J, Barrera JM, Rodes J. Posttransfusional versus sporadic non-A, non-B chronic hepatitis: a clinicopathological and evolutive study. Liver 1988;8:42-47.
3. Gordon SC, Elloway RS, Long JC, Dmuchowski CE The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. HEPATOLOGY 1993;18:1338-1343.
4. Alter MJ, Margolis HS, Krawczynski K, Judson EN, Mares A, Alexander WJ, Hu PYH, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
5. Roudot-Thoraval E. Bastie A, Pawlotski JM, Dhumeaux D, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. HEPATOLOGY 1997;26:491-494.
6. Kodali V, Gordon SC, McCray DG, Silverman AL. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, non-C hepatitis. Am J Gastroenterol 1994;89:1836-1839.
7. Silverman AL, Piquette DL, Filipiak CL, Neill JS, Bayati N, Gordon SC. Alfa-interferon treatment of HCV RNA positive patients with normal or near-normal ALT levels. Am J Gastroenterol 1997;92:1793-1795.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
9. Peto R, Pike MC. Conservatism of the approximation (O-E)/E in the logrank test for survival data on tumor incidences data. Biometrics 1973;29:579-584.
10. Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute Inc., 1995.
11. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
12. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
13. Mattson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-278.
14. Fattovich GF, Giustina G, Degos F, Tremolada F, Diodati G, Almasio E Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
16. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of hepatitis C. HEPATOLOGY 1996;23:1334-1340.
17. Merrican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. QJ Med 1991;86:119-125.
18. Fenster LE Viral hepatitis in the elderly: an analysis of 23 patients over 65 years of age. Gastroenterology 1965;49:262.
19. Lee DH, Jamal H, Regenstein FG, Perillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997;42:186-191.
20. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomized trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
21. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-4972.
22. Gordon SC, Kodali VP, Silverman AL, Dmuchowski C, Urdea MS, Chan C, Wilber JC. Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. Am J Gastroenterol 1994;89:1458-1461.
23. Lau JYN, Davis GL, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
24. Serfaty L, Chazouilleres O, Poujol-Robert A, Mourand-Joubert L, Dubois C, Chreitien Y, Poupon RE, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. HEPATOLOGY 1997;26:776-779